Completed PHASE1 INTERVENTIONAL 2-arm NCT01964872

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-38877618 in Healthy Male Participants

A Double Blind, Placebo-Controlled, Randomized, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-38877618 in Healthy Male Subjects

Sponsor: Janssen Cilag N.V./S.A.

Conditions Healthy Volunteers

Interventions JNJ-38877618: Part 1a JNJ-38877618: Part 1b JNJ-38877618: Part 1c (optional) JNJ-38877618: Part 2 JNJ-38877618: Part 3 JNJ-38877618: Part 4 (optional) Placebo: Parts 1a, 2, 3, and 4 (optional)

Updated 5 times since 2017 Last updated: Sep 11, 2014 Started: Nov 30, 2013 Primary completion: May 31, 2014 Completion: May 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy Volunteers, this trial is completed. The trial is conducted by Janssen Cilag N.V./S.A. and has accumulated 5 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Nov 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen Cilag N.V./S.A.

Data source: Janssen Cilag N.V./S.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nottingham, United Kingdom